Novacyt « Terug naar discussie overzicht

nieuws Novacyt

223 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 | Laatste

Omlaag ↓

voda 1 mei 2024 16:10

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

DHSC application for summary judgment dismissed

Paris, France, and Eastleigh and Manchester, UK - 1 May 2024 - Following the announcement on 19 April 2024, Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, notes the judgment by Mrs Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment.

The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.

www.voxmarkets.co.uk/rns/announcement...

RAMO 22 mei 2024 16:14

www.research-tree.com/newsfeed/articl...

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Notice of Results and Annual General Meeting

Paris, France, and Eastleigh and Manchester, UK - 20 May 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its audited financial results for the year ended 31 December 2023 on Thursday, 30 May 2024.

The Company also announces that its Annual General Meeting ("AGM") will be held at 2pm CEST/1pm BST on Wednesday, 26 June 2024 as an open virtual meeting. Further details of the AGM will be provided to shareholders in due course.

Investor webinar

An investor webinar presentation by Lyn Rees, Chief Executive Officer, and Steve Gibson, Chief Financial Officer, relating to the FY 2023 results will take place at 11.00am BST on Thursday, 30 May 2024.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Automated French subtitling will be available throughout the presentation.

voda 30 mei 2024 11:20

30 May NCYT – Full Year 2023 Results (30.05.2024)
in Board, News

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

Full Year 2023 results
Integration of Yourgene Health remains on track
Laying the foundations for future growth

Paris, France, and Eastleigh and Manchester, UK – 30 May 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces its audited results for the year ended 31 December 2023. The results include almost four months’ trading of Yourgene Health Limited (formerly plc) (“Yourgene”) following its acquisition by the Group, which completed on 8 September 2023.

Operational Highlights (including post year-end and Yourgene 2023 activities pre-acquisition)

Completed the strategic acquisition of Yourgene, significantly enhancing Novacyt’s global diagnostics business, adding scale and diversification to accelerate long-term growth.
Lyn Rees and John Brown CBE joined the Novacyt Board as Executive and Non-Executive Director respectively.
Lyn Rees appointed Chief Executive Officer following a six-year tenure as CEO of Yourgene Health plc, bringing over 28 years’ global healthcare leadership and commercial experience.
Steve Gibson appointed CFO, and to join the Board along with Dr Jo Mason, CSO, subject to shareholder approval.
IVDR certification: received first IVDR accreditation for the Yourgene DPYD genotyping assay for chemotoxicity in chemotherapy patients; submitted application for Cystic Fibrosis quantitative fluorescence PCR (QF-PCR) test.
Yourgene became a compatible partner of PacBio, a leading global developer of sequencing technology, supporting the use of the LightBench™ instrument (Ranger® Technology) to its global customer base.
Yourgene launched MagBench™ automated DNA extraction platform for NIPT workflows in Asia-Pacific and the Middle East.
Launch of the Primer Design Co-Prep ES instrument, providing automated DNA and RNA extraction using Primer Design assays, for use in multiple applications.
Primer Design launched a range of “complete” assays, including customised mastermix reagent for RUO customers.

Financial Highlights

Acquired the AIM-listed company Yourgene and its subsidiaries for an all-cash consideration of £16.7m on 8 September 2023.
Group statutory revenue for FY2023 was £11.6m, in line with guidance, of which £0.6m relates to COVID-19 (FY2022*: £21.0m, of which £14.7m related to COVID-19).
Group statutory revenue for the non-COVID-19 portfolio of £11.0m represents circa 95% of total revenue (FY2022*: £6.3m).
Group gross profit totalled £3.7m (32%) in FY2023 (FY2022: £5.7m (27%)). This was reduced predominantly as a result of providing for all remaining COVID-19 associated stock, in addition to writing off stock that had not been provided for previously. Excluding the impact of these items, the Group gross profit margin would be in excess of 60%.
Group EBITDA loss in FY2023 totalled £13.7m before exceptional items (FY2022: £13.5m loss).
Loss after tax increased to £28.3m in FY2023 (FY2022: £25.7m loss).
Completed cost savings actions that will deliver over £4.0m of bottom-line improvement, the Group is tracking ahead of schedule on the targeted synergies to be achieved from the Yourgene acquisition.
Cash position at 31 December 2023 was £44.1m (2022: £87.0m), reflecting the cash consideration and associated costs of the acquisition of Yourgene. The Group remains debt free.

*excludes any Yourgene revenue as pre-acquisition

Commenting on the results Lyn Rees, CEO of Novacyt, said: “2023 was a transitional year for Novacyt, during which the Group completed the acquisition of Yourgene, a significant milestone that has enhanced our global diagnostics capabilities, diversified our product portfolio and increased the scale of our non-COVID-19 revenues.

“We continue to focus all efforts towards working as a single business so that the reorganisation of the Group and the resulting synergies will leave us well placed to deliver future growth. We remain focused on driving the global sales of our key clinical and instrumentation products, while also rebuilding our RUO business. The Board believes that investment in R&D combined with our commercial strength is key to achieving long-term growth and we are increasingly well-placed to execute our business strategy.”

novacyt.com/ncyt-full-year-2023-resul...

223 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	31 mei 2024 17:35
Koers	0,656
Verschil	-0,017 (-2,53%)
Hoog	0,686
Laag	0,652
Volume	160.500
Volume gemiddeld	209.780
Volume gisteren	980.725

nieuws Novacyt

Meedoen aan de discussie?

Direct naar Forum

Detail

Novacyt nieuws meer